Peak Asset Management LLC Buys New Stake in Stryker Corporation $SYK

Peak Asset Management LLC purchased a new position in shares of Stryker Corporation (NYSE:SYK) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 52,332 shares of the medical technology company’s stock, valued at approximately $16,476,000. Stryker makes up 2.4% of Peak Asset Management LLC’s holdings, making the stock its 15th largest holding.

A number of other institutional investors also recently made changes to their positions in the stock. Gables Capital Management Inc. purchased a new position in Stryker in the 2nd quarter valued at about $25,000. Kilter Group LLC purchased a new position in shares of Stryker during the second quarter valued at approximately $25,000. Godfrey Financial Associates Inc. acquired a new stake in Stryker during the fourth quarter worth approximately $26,000. Sankala Group LLC purchased a new stake in Stryker in the 4th quarter worth approximately $26,000. Finally, Compass Financial Management LLC purchased a new stake in Stryker in the 2nd quarter worth approximately $27,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 300,000 shares of Stryker stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the sale, the director owned 2,301,375 shares of the company’s stock, valued at $773,031,862.50. The trade was a 11.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Debra King sold 826 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider owned 6,210 shares in the company, valued at $2,088,423. This represents a 11.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 355,370 shares of company stock valued at $119,447,201. Corporate insiders own 4.60% of the company’s stock.

Stryker Stock Performance

Shares of NYSE:SYK opened at $327.80 on Tuesday. The business has a 50-day moving average of $327.39 and a two-hundred day moving average of $332.16. The firm has a market capitalization of $125.73 billion, a PE ratio of 33.97, a P/E/G ratio of 2.10 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.86.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. During the same quarter in the previous year, the business earned $3.13 EPS. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, research analysts forecast that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Wall Street Analyst Weigh In

SYK has been the topic of several analyst reports. Leerink Partners decreased their price objective on Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a report on Friday, June 5th. Piper Sandler decreased their price target on Stryker from $420.00 to $390.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. Canaccord Genuity Group lowered their price target on Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a report on Friday, May 1st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Stryker in a research note on Friday, July 31st. Finally, Barclays decreased their target price on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research report on Monday, May 4th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.